Imunopatologia do SARS-COV-2: uma revisão

Autores

Palavras-chave:

SARS-CoV-2, COVID-19, Resposta imune humoral, anticorpos

Resumo

O conhecimento da dinâmica do vírus e a resposta do hospedeiro contra o mesmo, são aspectos essenciais para adoptar medidas eficazes para o tratamento antiviral, vacinação e controlo epidemiológico da COVID-19. A presente revisão teve como objectivo, analisar publicações sobre a dinâmica da resposta imunitária em indivíduos infectados pelo SARS-CoV-2. A resposta imunitária na COVID-19 tem início com a interacção entre a proteína S do SARS-CoV-2 e a enzima de conversão da angiotensina II (ACE2) na superfície da célula hospedeira. Esta interacção conduz a produção de interferões do tipo I (IFN-α e IFN-β) e citocinas pró-inflamatórias as quais são importantes na protecção das células não infectadas. No entanto, a resposta imunitária contra o SARS-CoV-2 é a principal responsável pelo quadro clínico da COVID-19 pelo facto das células T citotóxicas promoverem a destruição das células alveolares comprometendo o funcionamento dos pulmões e pelo facto de o vírus estimular a produção de uma tempestade de citocinas pró-inflamatórias responsáveis pela vasodilatação de pequenos vasos sanguíneos e a constrição da musculatura lisa do organismo podendo levar deste modo a uma falha multiorgânica. Portanto, podemos perceber que a produção de anticorpos específicos (IgM e IgG) ocorre entre os 14-21 dias após os primeiros sintomas da doença e declinam por volta da de 2 á a 5 semana após a infecção denotando uma curta durabilidade da imunoprotecção o que pode levar aos indivíduos recuperados uma susceptibilidade de reinfecção após este período.

Referências

Neher RA, Dyrdak R, Druelle V, et al. Potentiaol impact of seasonal forcing on a SARS-CoV-2 pandemic. 2020. Swiss Med Wkly. 2020; 150:w20224. https://doi.org/10.4414/smw.2020.20224.

WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency commitee regarding the outbreak of novel coronavirus (2019-nCoV). [Online].; 2020 [cited 2020 Abril 19. Available from: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov).

Gorbalenya AE, Baker SC, Baric RS, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5: 536–544. https://doi.org/10.1038/s41564-020-0695-z

Burrell CJ, Howard CR, Murphy FA. Fenner and White´s Medical Virology. 5th ed.: Elsevier; 2016.

Payne S. Viruses: From Understanding to Investigation. 1st ed.: Elsevier; 2018.

King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ. Virus Taxonomy: Classification and Nomenclature of Viruses. ; 2016.

Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 9th ed. Philadelphia: Elsevier; 2018.

Chen Y, Li L. SARS-CoV-2: virus dynamics and host response. Lancet Infect Dis. 2020; 20 (5). :515-516. https://doi.org/10.1016/S1473-3099(20)30235-8.

Sigrist CJA, Bridge A, Mercier PL. A potential role for integrins in host cell entry by SARS-CoV-2. Antiviral Research. 2020;177:104759 https://doi.org/10.1016/j.antiviral.2020.104759.

Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-432. https://doi.org/10.1002/jmv.25685.

Cao X. COVID-19: immunopathology and its implications for therapy. Nature Reviews/Immunology. 2020;20:269-270. https://doi.org/10.1038/s41577-020-0308-3.

Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181-193. https://doi.org/10.1016/j.chom.2016.01.007.

Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis & Rheumatology. 2020;72(7):1059-1063. https://doi.org/10.1002/art.41285.

Qin C, Zhou L, Hu Z, Zhang S, Yang S, MD YT, et al. Dysregulation of Immune Response in Patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases. 2020;71(15):762-768. https://doi.org/10.1093/cid/ciaa248.

Shi Y, Tan M, Chen X, Liu Y, Huang J, Ou J, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. medRxiv preprint. 2020. https://doi.org/10.1101/2020.03.12.20034736.

Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. Journal of General Virology. 2020;101(8):791-797. https://doi.org/10.1099/jgv.0.001439.

Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020b;20:845-848. https://doi.org/10.1038/s41591-020-0897-1.

Zhao J, Yuan Q, Wang H, Wei Liu 2, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;ciaa344. https://doi.org/10.1093/cid/ciaa344.

Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020a;26:1200-1204 https://doi.org/10.1038/s41591-020-0965-6.

Li SW, Wang CY, Jou YJ, Huang SH, Hsiao LH, Wan L, et al. SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway Through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6. Int. J. Mol. Sci. 2016;17(5):678. https://doi.org/10.3390/ijms17050678.

Lui PY, Wong LYR, Fung CL, Siu KL, Yeung ML, Yuen KS, et al. Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3. Emerging Microbes & Infections. 2016;5(1):1-9. https://doi.org/10.1038/emi.2016.33.

Oudshoorn D, Rijs K, Limpens RWAL, Groen K, Koster AJ, Snijder EJ, et al. Expression and Cleavage of Middle East Respiratory Syndrome Coronavirus nsp3-4 Polyprotein Induce the Formation of Double-Membrane Vesicles That Mimic Those Associated with Coronaviral RNA Replication. mBio. 2017;8(6)e01658-17. https://doi.org/10.1128/mBio.01658-17.

Swiss Institute of Bioinformatics. Viralzone. [Online].; 2020 [cited 2020 April 19. Available from: https://viralzone.expasy.org/9056.

Downloads

Publicado

12-12-2020

Como Citar

Catau , M. . (2020). Imunopatologia do SARS-COV-2: uma revisão. Revista Sol Nascente, 9(2), 69–79. Obtido de http://revista.ispsn.org/index.php/rsn/article/view/25